Company
Business
Stem Cell Therapy
Organoid
CDMO Business
IR Resource Center
Kangstem Biotech strives to develop an innovative new drug for patients suffering from rare and incurable diseases.
Japan Regenerative Medical Planning Engineer
27
2025.02
On February 26, 2025, an article regarding Kangstem Biotech’s regenerative medicine business in Japan was published in Edaily.
On February 26, 2025, an article regarding Kangstem Biotech’s regenerative medicine business in Japan was published in Edaily.
The article discusses the approval status and future performance outlook of Furestem-AD Injection, an atopic treatment, and autologous adipose stem cell-based therapies in Japan, a leading country in regenerative medicine.
Furestem-AD Injection is currently undergoing the final approval process by the Ministry of Health, Labour and Welfare(MHLW) in Japan, after receiving approval from the Committee on Specific Regenerative Medicine, based on the safety and efficacy data obtained from domestic clinical trials.
Additionally, the autologous adipose stem cell-based therapy has received final approval from the MHLW and is about to begin patient treatments. Steady revenue growth is expected through ongoing collaboration with local medical institutions in Japan.
For more details, you can check the link below.